Shire plc, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Ireland (IE) and operates extensively across Europe, North America, and Asia. Founded in 1986, Shire has established itself as a leader in developing innovative therapies for rare diseases and complex conditions, focusing on areas such as neuroscience, immunology, and genetic disorders.
The company is renowned for its unique portfolio of products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic disorders, which set it apart in a competitive market. Shire's commitment to research and development has led to significant milestones, including numerous FDA approvals and a strong market position, making it a trusted name in the pharmaceutical sector. With a dedication to improving patient outcomes, Shire continues to advance its mission of transforming the lives of those with challenging health conditions.
+20 vs industry average
Shire plc’s score of 60 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Shire plc?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
Scope 3 accounts for ••• of total emissions.
Shire plc's reported carbon emissions
Shire plc, headquartered in IE and operating within the Pharmaceutical Preparation Manufacturing industry, reported total carbon emissions of approximately 83.1 billion kg CO2e for the year 2016. This total encompasses Scope 1, Scope 2, and Scope 3 emissions.
Specifically for 2016, Scope 1 emissions were approximately 26.2 billion kg CO2e, and Scope 2 emissions amounted to about 118 billion kg CO2e. Scope 3 emissions for the same year were approximately 34.1 billion kg CO2e. The combined Scope 1 and 2 emissions totalled approximately 49 billion kg CO2e.
Data prior to 2016, such as for 2015, is not available in the provided information, with no emissions data disclosed for that year.
Shire plc's emissions data for 2016 is inherited from its parent organisation, Takeda Pharmaceutical Company Limited, as Shire plc is a current subsidiary. While Shire plc is listed as a source for CDP reporting at cascade level 0, its SBTi and RTZ reduction targets are cascaded from Takeda Pharmaceutical Company Limited at cascade level 1.
There are no specific reduction targets or achievements mentioned for Shire plc in the provided documentation.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Shire plc’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Shire plc yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Takeda Pharmaceutical Company Limited
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Takeda Pharmaceutical Company Limited
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Shire plc
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project